@Article{Sałata-Nowak2010,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="97",
number="3",
year="2010",
title="What should dermatologists know about osteoporosis?",
abstract="Prolonged glucocorticosteroid therapy is the most common cause of secondary osteoporosis, named glucocorticoid-induced osteoporosis. It is estimated that 30 to 50% of chronic glucocorticosteroid users experience vertebral or hip fractures. Prevention of osteoporosis is a very important public health concern. Dermatologists are among the leading prescribers of oral glucocorticosteroids; therefore, this topic is of utmost importance. Dermatological patients treated with glucocorticosteroids for longer than 3 months should receive prophylactic treatment to decrease the risk of bone loss. When glucocorticoids are used for a period shorter than 3 months, current literature does not suggest prophylaxis. All patients starting glucocorticosteroid treatment should be given instructions on general measures for prevention of bone loss.",
author="Sałata-Nowak, Justyna
and Flisiak, Iwona
and Chodynicka, Bożena",
pages="212--218",
url="https://www.termedia.pl/What-should-dermatologists-know-about-osteoporosis-,56,15049,1,1.html"
}